BlossomHill Therapeutics
BLSM · United States
Share price · BLSM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BLSM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+13.2%
Nothing announced by BLSM that day or the session before.
- 26 Oct 2026+12.0%
Nothing announced by BLSM that day or the session before.
Share of unusual movement by asset
For each asset, the share of BLSM's own-move activity since 10 Aug 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $22M | $225M | $24M-$22M operating cash flow | report ↗ |
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $21M | $95M | $24M | report ↗ |
| 2025-Q3 | — | $15M | $68M | $16M-$12M operating cash flow | report ↗ |
| 2025-Q2 | — | $13M | $79M | $13M | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $137M | — | report ↗ |
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | — | $100M | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 7 purchases ($25.2M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-10 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC · director; director | Conversion | 1,039,996 | — | — | Form 4 |
| 2026-08-10 | GORDON CARL L · director | Conversion | 1,039,996 | — | — | Form 4 |
| 2026-08-10 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC · director; director | Conversion | 1,049,283 | — | — | Form 4 |
| 2026-08-10 | GORDON CARL L · director | Conversion | 1,049,283 | — | — | Form 4 |
| 2026-08-10 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC · director; director | Open-market purchase | 625,000 | $16.00 | $10.0M | Form 4 |
| 2026-08-10 | GORDON CARL L · director | Open-market purchase | 625,000 | $16.00 | $10.0M | Form 4 |
| 2026-08-10 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC · director; director | Conversion (derivative) | 1,039,996 | — | — | Form 4 |
| 2026-08-10 | GORDON CARL L · director | Conversion (derivative) | 1,039,996 | — | — | Form 4 |